We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)

Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)

SEKISUI Diagnostics (Burlington, MA, USA) displayed its point-of-care rapid diagnostics and clinical chemistry reagents at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

This year’s 2021 AACC was held in partnership with the Canadian Society of Clinical Chemists (CSCC) at the Georgia World Congress Center in Atlanta, September 26-30. SEKISUI Diagnostics delivers differentiated products, instrument systems, and services that support the improvement of patient care worldwide. The company is a recognized leader in the development, manufacture, and supply of innovative clinical chemistry reagents and systems that enhance the clinical chemistry laboratory function. Over 1.7 billion tests are performed each year using the company’s products. With a broad line of >65 reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays, SEKISUI is well-poised to meet individual needs.

At AACC 2021, SEKISUI displayed its OSOM rapid diagnostics that offers a variety of family and women’s health products, and services. These diagnostic tests allow healthcare professionals to cost effectively diagnose at the point-of-care in one visit, thus reducing labor and follow-up time while increasing patient satisfaction. The company also demonstrated its Acucy System that provides clinicians with flexibility in workflow and accurate, standardized results for improved patient care.

Also on display was SEKISUI’s FastPack IP System which is a fully automated quantitative immunoassay analyzer designed for use in any size physician office laboratory and provides results in 12 minutes or less with the push of a button. Offering real-time testing with a simple three-step process, the system enables healthcare professionals to diagnose, monitor, and adjust therapy in one patient visit.

Related Links:
SEKISUI Diagnostics

Visit expo >

New

Gold Member

Neonatal Heel Incision Device

Tenderfoot

Online QC Software
Acusera 24•7

New

CMV CLIA Diagnostic

CLIA CMV IgA Screen Group

New

Electrolyte Analyzer

CBS-4000 (CBS-400)

Latest Clinical Chem. News

Channels

Clinical Chemistry

view channel

Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing

Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read more

CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics

Specialized care settings frequently evaluate patients aged 50 years and older who present with signs and symptoms of cognitive decline to determine whether amyloid pathology linked to Alzheimer’s disease... Read more

Molecular Diagnostics

view channel

Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer

Accurate identification of aggressive prostate cancer subtypes can be difficult when tumors lose expression of lineage markers used in routine pathology. Small cell carcinoma of the prostate, in particular,... Read more

Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample

Cepheid’s Xpert GI Panel has received CE marking under the In Vitro Diagnostic Medical Devices Regulation (IVDR) and is expected to begin shipping to countries that accept the CE mark in the coming weeks.... Read more

Novel Algorithm Improves Detection of B-ALL Gene Fusions

B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer, requires accurate genomic subtyping to guide risk-stratified treatment. However, identifying fusion oncogenes can be limited... Read more

Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Hematology

view channel

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Blood Test Enables Early Detection of Multiple Myeloma Relapse

Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more

Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more

Immunology

view channel

Routine TB Screening Test May Reveal Immune Aging and Mortality Risk

Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more

Biomarkers and Molecular Testing Advance Precision Allergy Care

Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more

Image: Schematic of Mpox diagnostic methods.(A) Artificial intelligence (AI)-enhanced image classification can be leveraged to classify lesions concerning for Mpox, particularly in low resource settings where specialists (i.e., infectious disease specialists or dermatologists) are not available. (B) Clinical specimens (including nasal swabs, lesion swabs, or serum samples) can be used for molecular or biochemical confirmation of Mpox infection. (C) Rapidly, field-deployable devices or assays can be developed using various strategies(Mpox) diagnostic methods (Yilgic D, Ergonul O, Tasoglu S. Mpox diagnosis at POC. Trends in Biotechnology. DOI: 0.1016/j.tibtech.2025.04.015)

Point-of-Care Tests Could Expand Access to Mpox Diagnosis

Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more

Image: Graphical abstract (Turano PS, Akbulut E, Dewald HK, et al. Cell Reports (2026). DOI: 10.1016/j.celrep.2025.116795)

T-Cell Senescence Profiling May Predict CAR T Responses

Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more

Microbiology

view channel

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more

Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more

Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients

Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more

Image: Biosensor for tuberculosis detection (photo courtesy of UPV)

Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour

Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more

Pathology

view channel

FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification

Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more

Image: Tissue sample spatial analysis (on left) and standard H&E image (on right) (Photo courtesy of QIMR Berghofer Medical Research Institute)

New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides

Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more

Image: SPARK overview, data structure and study design (Trost, F., Zhang, B., Aring, I. et al. https://doi.org/10.1038/s41591-026-04357-y)

AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes

The digital transformation of pathology is expanding how cancers are evaluated in routine practice. Artificial intelligence (AI) is increasingly applied to routinely collected histological tissue sections,... Read more

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more

Technology

view channel

Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease

Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more

Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing

Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more

Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response

Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more

New Platform Captures Extracellular Vesicles for Early Cancer Detection

Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more

Industry

view channel

Image: Ozelle Wins German Innovation Award Gold (photo courtesy of Ozelle)

AI-Powered Multi-Functional Analyzer Wins German Innovation Award

Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more

Partnership Aims to Bring Risk-Guided CKD Care to Health Systems

Chronic kidney disease (CKD) places a substantial clinical and financial burden on the United States. As health systems face growing pressure to detect risk earlier and manage progression proactively,... Read more

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio

Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy

Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more